Plus Therapeutics, Inc. (NASDAQ: PSTV) disclosed today that its continuing ReSPECT Phase I trial has shown positive results. In the clinical trial, the firm is assessing Rhenium NanoLiposome (RNL) in patients with recurrent glioblastoma (GBM). RNL is meant to deliver a very high dose